Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $67 from $43 and keeps a Hold rating on the shares. Based on the firm’s view that the total TTR-CM category is likely going to be even bigger than it had anticipated and that eplontersen, per key opinion leaders, is poised to garner meaningful share, the firm is raising its estimates for Ionis and AstraZeneca’s (AZN) eplontersen in TTR-CM, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Private Markets: Cerebras raises $1B in pre-IPO funding round
- Ionis Pharmaceuticals: Strategic Advancements and Market Opportunities Amidst Competitive Challenges
- CarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
- Ionis Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
- Ionis Pharmaceuticals price target raised to $80 from $78 at Barclays